Status:
COMPLETED
Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan
Lead Sponsor:
Bayer
Conditions:
Non-Hodgkin's Lymphoma (NHL)
Eligibility:
All Genders
Brief Summary
This study is a regulatory post-marketing surveillance of Zevalin (ibritumomab tiuxetan) in Japan. In-111 Zevalin is, at first, injected to patient for gamma scan imaging to assess biodistribution of ...
Eligibility Criteria
Inclusion
- Patients who received In-111 Zevalin to verify that expected biodistribution is present.
Exclusion
- Patients who are contraindicated based on the product label.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT01479387
Start Date
August 1 2008
End Date
February 1 2011
Last Update
November 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Japan